Presentation is loading. Please wait.

Presentation is loading. Please wait.

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Published bySamantha Hubbard Modified over 6 years ago

Similar presentations

Presentation on theme: "MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet"— Presentation transcript:

1 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet
Study of Access For Enhancement of STEMI for Seniors: The SAFE STEMI for Seniors Protocol Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director, MDEpiNet Coordinating Center Duke Clinical Research Institute MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

2 Disclosure Statement of Financial Interest
Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit Company Names

3 Conflicts No personal stock, holdings or IP
No corporate revenue >$50k per annum Research grants, consulting relationships: Abbott Vascular Acist Medical Biosensors Boston Scientific Cook Medical Cordis J&J CSI Medtronic OrbusNeich St. Jude Medical Terumo

4 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet
What is SAFE STEMI for Seniors? Combining public health and regulatory science A new approach to STEMI in seniors: 100% STEMI, 100% “radial first” strategy Prospective RCT: IRA-only vs. complete revasc A new approach to medical device trials: Registry-based randomized trials: less site based work load faster enrollment More efficient regulatory decisions: complementary clinical questions for labelling (IDE) partnered manufacturer-sponsors MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

5 Why SAFE STEMI for Seniors?
SENIORS: The Role of Age in STEMI Complications from STEMI: Highest mortality Highest MACE rates Complications from therapies: Bleeding rates Vascular complications Other peri-procedural complications Complications with billable (Medicare) services Claims data documentation MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

6 Ready for prime time? Ready for seniors? …..in the USA???
“Radial-first” STEMI Ready for prime time? Ready for seniors? …..in the USA??? MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

7 RIVAL: 5,063 non-STEMI, 1,958 STEMI RIFLE STEACS: 1,000 STEMI
MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Jolly SS et al Lancet 2011 Romagnoli E et al JACC 2013

8 MATRIX: ACS (STEMI & Non-STEMI)
MACE NET DEATH 8,404 patients RCT TRI vs TFI Numerically lower MACE & mortality Significantly lower Net clinical benefit BARC Valmigli M et al, Lancet 2015;385:

9 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet
Novel Trial Structure 21st Century Regulatory Science: Registry-based randomized trials The NEST Context MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

10 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet
National Evaluation System for Health Tech (NEST) Real World Evidence of Device Benefit/Risk, Safety Krucoff MW, Normand SL et al, JAMA 2015 Shuren J, Califf R, JAMA Published online July 11, 2016 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

11 TCT 2013 Featured LBCT A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access Enhancement of PCI for Women (SAFE-PCI for Women) Trial Sunil V. Rao MD, Connie N. Hess MD, Britt Barham, Laura H. Aberle, Kevin Anstrom PhD, Tejan B. Patel MD, Jesse P. Jorgensen MD, Ernest L. Mazzaferri MD, Sanjit S. Jolly MD, Alice Jacobs MD, L. Kristin Newby MD, C. Michael Gibson MD, David F. Kong MD, Roxana Mehran MD, Ron Waksman MD, Ian C. Gilchrist MD, Brian J. McCourt, Eric D. Peterson MD MPH, Robert A. Harrington MD, Mitchell W. Krucoff MD on behalf of the SAFE-PCI for Women Investigators

12 SAFE-PCI for Women workflow
Randomization Demographics Medical Hx Procedural data Index Hosp MACE Autopopulate Part 11 Compliant 65% site coordinator workload reduction Unique pages for trial Analytic Database

13 Efficiency Accelerates Enrollment

14 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet
September 2013 Lauer M et al, NEJM 2013 Hess C et al, Am Heart J 2013 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Rao S et al JACC Cardiovascular Int 7(8)2014

15 SAFE STEMI for Seniors: Study Design
IDE

16 Patient Flows IDE MV PCI in STEMI PRAMI CvLPRIT

17 SAFE STEMI for Seniors: Linked NCDR-Claims Data “CRN” Structure
Index Procedure Clinical Follow-up: Administrative Data n=1,000 Safety evaluation of Edwards Sapien heart valve in general practice Follow-up to 5 years: Detailed registry follow-up for year 1 Medicare claims follow-up for full time interval Comparator: Objective Performance Criteria (OPC) based on prior trial data Innovations in Efficient follow-up for post-market studies: Algorithm-assisted endpoints Medicare linkage This study will require patient-level consent because of the need for additional clinical follow-up that was considered outside the standard of care. 2 Registry-sponsored observational IDE studies are under review with FDA for label extension. These were designed to only include ‘standard of care’ clinical follow-up & may not require individual patient-level consent. CRF data from Clinical Registry Index AMI Hospitalization 1mo 1 yr 2 yrs 3 yrs 4 yrs 5 yrs Months

18 SAFE STEMI for Seniors: Conclusions
Public health clinical trial: Radial access PCI in seniors Multivessel PCI in seniors Partnered manufacturer IDE: DES labelling for STEMI (Medtronic) iFR guided multivessel PCI (Volcano-Philips) 21st Century regulatory science Registry-based (CRN) RCT: Index procedure (NCDR Cath-PCI) Long term follow up (Claims data) MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

19 What is SAFE STEMI for Seniors?
Public health clinical trial: >65 y.o STEMI <6 hrs Radial access PCI in seniors Multivessel PCI in seniors IDE(s) clinical trial: DES labelling for STEMI (Medtronic) iFR guided multivessel PCI (Volcano-Philips) Registry-based CRN randomized trial: Index procedure (NCDR Cath-PCI) Long term follow up (Claims data) Lesson in partnered problem solving MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

20 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet
Study of Access For Enhancement of STEMI for Seniors: The SAFE STEMI for Seniors Protocol Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director, MDEpiNet Coordinating Center Duke Clinical Research Institute MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Download ppt "MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet"

Similar presentations

OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.

OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.
A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access site.

A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access site.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
[name of file], 1 From Cardiac Safety To SAFE PCI Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director,

[name of file], 1 From Cardiac Safety To SAFE PCI Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director,
A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access Enhancement.

A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access Enhancement.
20090417 Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /

Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.

1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.

Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.

Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.

Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Title of Presentation Presenter Name, Designation Presenter 2 Name, Designation Presenter 3 Name, Designation.

Title of Presentation Presenter Name, Designation Presenter 2 Name, Designation Presenter 3 Name, Designation.
CIT 2016 Template Title 40 pt Bold Arial David Liu, MD Subtitle 34 pt Arial Bold Italics.

CIT 2016 Template Title 40 pt Bold Arial David Liu, MD Subtitle 34 pt Arial Bold Italics.
1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.

1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.

Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and

Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Transradial Best Practices for Radial Access

Transradial Best Practices for Radial Access
My Best Radial Case of the Past Year ... And what I learned from it

My Best Radial Case of the Past Year ... And what I learned from it
Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.

Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.
Leveraging Bayesian Methodology to Increase the Trial Efficiency

Leveraging Bayesian Methodology to Increase the Trial Efficiency
David E. Kandzari, MD on behalf of the BIONICS investigators

David E. Kandzari, MD on behalf of the BIONICS investigators

Similar presentations

Ads by Google